Oncology Pharma Inc. and Kalos Therapeutics announced that the companies amended the terms of their collaboration to explore treatment opportunities of the COVID-19 virus, for the benefit of the most vulnerable cancer patients with cardiovascular issues and/or a weakened immune system. George Colberg, Chairman and CEO of Kalos Therapeutics, and Dr. Vijay Mahant, Chief Scientific Officer of Oncology Pharma, have proposed the investigation of Kalos Therapeutics’ lead drug KTH-222 (alone and/or in combination with anti-viral drugs) as an integral part of monitoring viral loads in cancer patients infected with the COVID-19 virus or in suspected patients with the symptoms. In 2019, Kalos Therapeutics signed a Letter of Intent with Oncology Pharma, for a worldwide license and co-development of Kalos's lead anti-cancer drug, KTH-222. The agreement centered on KTH-222 as a mono-therapy and/or in combination with antiviral drugs or therapies approved by the FDA and/or the appropriate regulatory agencies.